乌司奴单抗治疗溃疡性结肠炎患者早期症状改善:UNIFI 试验 16 周数据
该研究为 UNIFI 试验的事后分析,纳入 961 例中重度活动性溃疡性结肠炎患者,按 1:1:1 随机接受静脉 130 mg 乌司奴单抗、约 6 mg/kg 乌司奴单抗或安慰剂。结果显示乌司奴单抗组在第 2 周症状缓解率显著高于安慰剂,第 7 天排便次数较基线下降更明显,部分 Mayo 评分、C 反应蛋白及粪钙卫蛋白正常化也较早改善。
要点
- 第 2 周症状缓解率:130 mg 组 20.0%(P=0.015)、约 6 mg/kg 组 20.2%(P=0.012),均高于安慰剂组 12.9%。
- 第 7 天每日排便次数较基线变化:130 mg 组 -1.1(P=0.065)、约 6 mg/kg 组 -1.2(P=0.017),安慰剂组 -0.7。
- 第 2 周起两乌司奴单抗组部分 Mayo 评分较安慰剂显著改善(P≤0.001)。
核心结论
- 乌司奴单抗可在最早 7 天内改善溃疡性结肠炎患者症状,提示诱导治疗后快速起效。
研究设计与样本
- UNIFI 试验(NCT02407236)的事后分析,纳入 961 例中重度活动性溃疡性结肠炎患者,按 1:1:1 随机接受静脉 130 mg 乌司奴单抗、约 6 mg/kg 乌司奴单抗或安慰剂(第 0 周)。
主要发现
- 第 2 周症状缓解率:130 mg 组 20.0%(P=0.015)、约 6 mg/kg 组 20.2%(P=0.012),均高于安慰剂组 12.9%。
- 第 7 天每日排便次数较基线平均变化:130 mg 组 -1.1(P=0.065)、约 6 mg/kg 组 -1.2(P=0.017),安慰剂组 -0.7。
- 两乌司奴单抗组 Mayo 排便频率亚评分≤1 且直肠出血亚评分为 0 的患者比例从基线至第 16 周增加。
- 两乌司奴单抗组第 2 周部分 Mayo 评分较安慰剂显著改善(P≤0.001)。
- 两乌司奴单抗组第 2 至 8 周 C 反应蛋白正常化患者显著多于安慰剂(P≤0.05),第 2 至 4 周粪钙卫蛋白正常化也观察到类似结果(P≤0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Rapid symptomatic relief is an important treatment goal for patients with ulcerative colitis (UC). We aimed to characterize early response with ustekinumab in patients with moderate-to-severe UC during the initial 16 weeks of treatment. METHODS: We performed a post hoc analysis of data from A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis trial. Patients (N = 961) were randomized (1:1:1) to receive intravenous 130 mg ustekinumab, approximately 6 mg/kg ustekinumab, or placebo at week 0. Symptomatic remission, absolute stool number, Mayo stool frequency and rectal bleeding subscores, partial Mayo score, C-reactive protein, and fecal calprotectin were assessed in the overall population and for patients in the biologic-naïve or prior biologic failure subgroups. RESULTS: A significantly greater percentage of patients in the 130-mg ustekinumab (20.0%; P = .015) or approximately 6-mg/kg ustekinumab (20.2%; P = .012) groups achieved symptomatic remission at week 2 vs placebo (12.9%). Mean [SD] changes from baseline in daily stool number on day 7 were greater in the ustekinumab groups (-1.1 [2.6] in 130 mg [P = .065] and -1.2 [2.5] in ∼6 mg/kg [P = .017]) vs placebo (-0.7 [2.7]). The percentage of patients with Mayo stool frequency subscore of 1 or less and rectal bleeding subscore of 0 increased from baseline through week 16 for both ustekinumab groups. Significant improvements in partial Mayo scores were observed by week 2 in both ustekinumab groups vs placebo (P ≤ .001). Significantly more patients in the ustekinumab groups had normalized C-reactive protein levels from week 2 to week 8 vs placebo (P ≤ .05). Similar results were observed with normalized fecal calprotectin levels between week 2 and week 4 (P ≤ .05). CONCLUSIONS: Ustekinumab improved symptoms in patients with UC compared with placebo in as early as 7 days, indicating rapid onset of effect after induction. CLINICAL TRIAL REGISTRY NUMBER: ClinicalTrials.gov: NCT02407236.
引用
- Danese S, Sands BE, Abreu MT, et al. Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial. Clin Gastroenterol Hepatol. 2022. PMID: 35276329. doi:10.1016/j.cgh.2022.02.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。